Clinical trials (e.g., CheckMate 142) have shown that baseline gut microbiota diversity correlates with response to anti-PD-1 therapy in CRC patients, with Akkermansia muciniphila abundance predicting improved outcomes (Figueiredo et al., 2014). This evidence concerns the gene PDCD1 and colorectal carcinoma.